secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2026-05-13T20:16:36+00:00
Accession:  0001193125-26-221677
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics Q1 net loss $45.5M; cash $379.8M; board resignations; vopimetostat combo data due 2026
--------------------------------------------------------------------------------

- Net loss $45.5M ($0.32/sh) vs $39.9M ($0.36/sh) YoY; R&D $33.5M, G&A $15.2M.
- Cash $379.8M as of March 31, 2026; runway into 2028.
- Directors Alexis Borisy and Kanishka Pothula resigned May 13; Sung Lee takes Lead Independent Director and Compensation Chair.
- Initial phase 1/2 data for vopimetostat + RAS(ON) inhibitors expected in 2026; registrational path being reviewed.
- New leadership appointments: Matthew Gall as CFO, Yen-Ching Chua as CDOO, Janice Kapty as SVP Corp Strategy (April 2026).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526221677/0001193125-26-221677-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000119312526221677/tngx-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-221677

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer